激素抵抗性前列腺癌化疗15例报告  

Clinical results of chemotherapy for hormone refractory prostate cancer:A report of 15 cases

作　　者：喻彬[1] 须霆[1] 邹青[1] 杨尔炘[1] 汪仪俊[1] 

机构地区：[1]江苏省肿瘤医院(江苏省肿瘤防治研究所)泌尿外科,江苏南京210009

出　　处：《现代肿瘤医学》2010年第4期748-749,共2页Journal of Modern Oncology

摘　　要：目的:探讨多西紫杉醇联合泼尼松治疗内分泌治疗失败前列腺癌的应用价值。方法:入选15例非激素依赖性前列腺癌患者,给予多西紫杉醇75 mg/m2,第1天;泼尼松5 mg bid,第1-21天,21天为1个周期,每例接受化疗6-10个周期不等。结果:本组病例随访6-87周,中位61周。其中26.7%(4/15)完全缓解,46.7%(7/15)部分缓解,20.0%(3/15)稳定,6.66%(1/15)进展。缓解和稳定患者的PSA进展中位时间是40.3周(13-67周)。8例骨痛患者中5例疼痛缓解。中位生存期大于12个月。不良反应可耐受。结论:多西紫杉醇联合泼尼松治疗激素抵抗性前列腺癌有较好疗效,不良反应轻。Objective：To evaluate the efficacy of docetaxel plus prednisone in treating hormone refractory prostate cancer and to evaluate it＇s adverse events.Methods：Fifteen patients with metastatic hormone refractory prostate cancer were candidated and given a combination of docetaxel 75mg/ m^2 intravenously on day 1 and prednisone 5 mg twice daily on day 1-21,21 days a cycle.Each patient accepted a chemotherapy of 6-8 cycles.Results：The patients were followed-up for 6-87 weeks（mean time 61 weeks）,26.7%（4 /15） of them got a complete response;46.7%（7/15） partial response;20.0%（3/15） stable disease;and 6.66%（1/15） progressed,and in the patients whose serum PSA decreased,the average time to PSA relapse was 40.3 weeks（13-67weeks）.Pain relief was seen in 5 out of 8 patients.The medium survival time was more tha 12 months.The toxicity of chemotherapy was tolerable.Conclusion：With minor toxicity,the combination of docetaxel plus prednisone has a certain effect on hormone refractory prostate cancer.

关 键 词：前列腺癌 激素抵抗 化疗 多西紫杉醇 

分 类 号：R737.25[医药卫生—肿瘤]